This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs

This study has been completed.
Information provided by (Responsible Party):
Jung-Hwan Yoon, Seoul National University Hospital Identifier:
First received: July 26, 2006
Last updated: December 2, 2013
Last verified: December 2013
The purpose of this study is to choose the preferred treatment modality for multiple, small hepatocellular carcinomas.

Condition Intervention Phase
Hepatocellular Carcinoma Procedure: Transarterial chemoembolization Procedure: Percutaneous ethanol injection therapy Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Controlled Trial of the Effective Therapy for Multiple, Small Hepatocellular Carcinomas: Comparing Transarterial Chemoembolization With Percutaneous Ethanol Injection Therapy.

Further study details as provided by Jung-Hwan Yoon, Seoul National University Hospital:

Primary Outcome Measures:
  • overall survival rate [ Time Frame: 5 year ]

Secondary Outcome Measures:
  • Disease free survival rate and recurrence rate [ Time Frame: 5 year ]

Enrollment: 22
Study Start Date: October 2005
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: chemotherapy
Transarterial chemoembolization (TACE)
Procedure: Transarterial chemoembolization
lipiodol, adriamycin and/or mitomycin
Other Name: TACE
Active Comparator: ethanol
Percutaneous ethanol injection therapy (PEIT)
Procedure: Percutaneous ethanol injection therapy
99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
Other Name: PEIT

Detailed Description:

To compare the below things between PEIT group and TACE group

  1. Survival

    1. 5 year overall survival rate
    2. Disease free survival rate
  2. Recurrence a. recurrence rate

Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The evidences of HBV(+) &/or HCV(+) infection or liver cirrhosis
  • Two to three tumor nodules with Child-Pugh classification A or single to three tumor nodules with Child-Pugh classification B
  • The maximal, longest diameter of tumor mass measured by CT finding should be less than 2 cm.
  • 1) Only for newly detected HCCs which were not treated before or 2) If treated before, it should be noted that there is no evidence of recurrence within the latest 6 months and, and also it should be remotely recurred more than 2cm apart from primary lesion.
  • It should be compatible with the typical findings of HCCs radiologically(MD CT or dynamic MRI)

Exclusion Criteria:

  • In case of hepatic vein or portal vein invasion radiologically(CT or MRI)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00357474

Korea, Republic of
Seoul NUH
Seoul, Chongno-gu, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
Principal Investigator: J H Yoon, Professor Seoul National University Hospital
  More Information

Responsible Party: Jung-Hwan Yoon, Professor, Seoul National University Hospital Identifier: NCT00357474     History of Changes
Other Study ID Numbers: 07-2006-010
Study First Received: July 26, 2006
Last Updated: December 2, 2013

Keywords provided by Jung-Hwan Yoon, Seoul National University Hospital:

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs processed this record on August 23, 2017